Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000005

Drug Information
Synonyms15039-60-8; Butanediamide, N4-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S-(N4(R*),2R*,3S*))-; D03795; (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; Marimastat [USAN]; CHEBI:50662; BB-2516; Butanediamide, N4-((1S)-2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)-; UNII-D5EQV23TDS; 154039-60-8; DB00786; CHEMBL279785; Butanediamide, N(sup 4)-(2,2-dimethyl-1-((methylamino)carbonyl)propyl)-N(sup 1),2-dihydroxy-3-(2-methylpropyl)-, (2S-(N(sup 4)(R*),2R*,3S*))-; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide; AC1L3O2N; C15H29N3O5; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; CID119031; Marimastat; C100342; LS-45634; BB 2516; Marimastat (USAN/INN); (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid    
CompanyBritish Biotech plc / Schering-Plough    
IndicationPancreatic Cancer, Lung CancerDiscontinued in Phase III    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 154039-60-8
PubChem Compound IDCID 119031.    
PubChem Substance IDSID 583701.    
Ref 1Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. To Reference
Ref 2Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. Epub 2006 Dec 12. To Reference
Ref 3Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009 Feb;15(2):RA32-40. To Reference
Ref 4Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. To Reference
Ref 516498445 To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543